EPISODE · Apr 1, 2025 · 1 MIN
Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies | JACC | ACC.25
from JACC This Week
This interview with JACC: Associate Editor Neha J. Pagidipati, MD, FACC, and author Kausik Ray, MD, FACC, reviews Dr. Ray's phase one study on solbinsiran, an siRNA therapy targeting ANGPTL3 to reduce triglycerides and cardiovascular risk. Dr. Ray explains the study's findings, including significant reductions in triglycerides, ApoB, and LDL, with a favorable safety profile. The conversation also touches on the broader landscape of ANGPTL3 inhibitors, the implications of HDL reduction, and the anticipation of phase two results to be presented at ACC 2025.
NOW PLAYING
Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies | JACC | ACC.25
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 3, 2026 ·44m
Feb 21, 2026 ·30m
Jan 2, 2026 ·47m